


TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
02940086CA

In Re Application Of: Peart et al.



Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/759,280	1-20-04	unknown	30743	1616	6861

Title: **DELTA TETRAHYDOCANNABINOL (DELTA9 THC) SOLUTION METERED DOSE INHALERS AND METHODS OF USE**

Address to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR 1.97(b)

- The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

- The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:
 - the statement specified in 37 CFR 1.97(e);


OR

- the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.95(b) or 1.97(c))

Docket No.
02940086CA

In Re Application of: Peart et al.



Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/759,280	1-20-04	unknown	30743	1616	6861

Title: **DELTA⁹TETRAHYDOCANNABINOL (DELTA9 THC) SOLUTION METERED DOSE INHALERS AND METHODS OF USE**

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

A check in the amount of _____ is attached.

The Director is hereby authorized to charge and credit Deposit Account No. **50-2041** as described below.

Charge the amount of _____
 Credit any overpayment.
 Charge any additional fee required.

Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

*This certificate may only be used if paying by deposit account.

Signature

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)]

(Date)

Signature of Person Mailing Correspondence

Typed or Printed Name of Person Mailing Certificate

Dated: **7-21-05**

Michael E. Whitham
Reg. No. 32,635
Whitham, Curtis & Christoffeson P.C.
11491 Sunset Hills Road
Suite 340
Reston, Va. 20190
Customer # 30743
703-787-9400

CC:



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of

Pearl et al.

Serial No. 10/759,280

Group Art Unit: 1616

Filed: 1-20-04

Examiner: unknown

For: **DELTA TETRAHYDOCANNABINOL (DELTA9 THC) SOLUTION
METERED DOSE INHALERS AND METHODS OF USE**

Commissioner for Patents
P.O. Box 1450
Alexandria, Va. 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Under the provisions of 37 C.F.R. 1.97 through 1.99 and pursuant to applicant's duty of disclosure under 37 C.F.R. 1.56, applicant respectfully brings the following documents, cited for the above-identified patent application and listed on the attached forms PTO-1449, to the attention of the Examiner in charge of the above-identified application. Copies of the listed documents are provided herewith for the convenience of the Examiner.

This citation does not constitute an admission that the references are relevant or material to the claims. They are only cited as constituting related art of which the applicant is aware.


Please charge any deficiencies in fees and credit any overpayment of fees to
Attorney's Deposit Account No. 50-2041.

Respectfully submitted,



Michael E. Whitham
Reg. No. 32,635

Whitham, Curtis & Christofferson P.C.
11491 Sunset Hills Road
Suite 340
Reston, Va. 20190
703-787-9400
Customer # 30743

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>				Docket Number (Optional) 02940086AA		Application Number 10/759,280		
				Applicant(s) Peart et al.		Filing Date 1-20-04		Group Art Unit 1616
 U.S. PATENT & TRADEMARK DOCUMENTS								
*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
U.S. PATENT APPLICATION PUBLICATIONS								
*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
FOREIGN PATENT DOCUMENTS								
	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation <input type="checkbox"/> YES <input type="checkbox"/> NO	
	1	WO 98/24420	6-11-98	PCT			<input type="checkbox"/>	<input checked="" type="checkbox"/>
OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>								
1	XP008034315, Ungerleider et al. "Cannabis and Cancer Chemotherapy" A comparison of Oral-9-THC and Prochlorperazine; American Cancer Society ppg. 636-345 1982							
2	XP-000961105, Vanchon et al. "Airways to Micro-Aerosolized Delta-9 Tetrahydronanol" 42 Annual Scientific Assembly; September 1976							
EXAMINER				DATE CONSIDERED				
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								